gliclazide

gliclazide
Drug name	Gliclazide
Routes of administration	Oral
Class	Sulfonylurea
Atc prefix	A10
Atc suffix	B01
Legal UK	POM

gliclazide is an oral hypoglycemic agent in the sulfonylurea class used to treat type 2 diabetes mellitus. It is prescribed to reduce fasting and postprandial hyperglycemia by stimulating pancreatic insulin secretion and improving glycemic control in adults. Clinical use has been influenced by guidelines from organizations such as the World Health Organization, American Diabetes Association, and International Diabetes Federation.

Medical uses

Gliclazide is indicated primarily for type 2 diabetes mellitus when lifestyle modification and metformin monotherapy are inadequate. Treatment aims align with targets advocated by American Diabetes Association standards of care, National Institute for Health and Care Excellence guidance, and regional authorities like European Medicines Agency and Food and Drug Administration-related frameworks. It has been compared in randomized trials against agents such as glipizide, glyburide, glimepiride, metformin, pioglitazone, and newer therapies including sitagliptin, liraglutide, and empagliflozin.

Mechanism of action

Gliclazide exerts its pharmacological effect by binding to sulfonylurea receptors on pancreatic beta-cell KATP channels, a target also implicated in studies of ATP-sensitive potassium channel, mitochondrial function, and insulin exocytosis mechanisms described in literature from institutions like Harvard Medical School and Johns Hopkins University. Binding reduces K+ efflux, leads to membrane depolarization, Ca2+ influx, and insulin granule fusion, a pathway explored in research from Karolinska Institutet and Imperial College London. Secondary effects on hepatic glucose production and peripheral insulin sensitivity have been evaluated in cohorts at Mayo Clinic, Cleveland Clinic and multicenter trials coordinated by World Health Organization initiatives.

Pharmacokinetics

After oral administration gliclazide is absorbed with pharmacokinetic profiles characterized in studies from University of Oxford, University of Cambridge, and University of Toronto. Peak plasma concentrations are reached within hours, with hepatic metabolism primarily via cytochrome P450s described in reports involving University College London and National Institutes of Health investigators. Elimination half-life varies with extended-release formulations developed in collaboration with pharmaceutical companies and examined in clinical pharmacology units at Massachusetts General Hospital and Karolinska University Hospital.

Adverse effects and safety

Common adverse effects include hypoglycemia, weight gain, and gastrointestinal symptoms; hypoglycemia risk has been highlighted in safety communications by World Health Organization and regional drug safety agencies such as European Medicines Agency pharmacovigilance committees. Rare but serious events like hematologic changes (e.g., hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency) and hepatic dysfunction have prompted screening recommendations from British Medical Association and specialty societies at American Association of Clinical Endocrinologists. Use in pregnancy and breastfeeding is discussed in position statements from American College of Obstetricians and Gynecologists and Royal College of Obstetricians and Gynaecologists.

Dosage and administration

Dosing strategies include immediate-release and modified-release regimens; titration protocols appear in clinical guidelines from National Institute for Health and Care Excellence, American Diabetes Association, and national formularies such as the British National Formulary and Australian Therapeutic Goods Administration monographs. Dose adjustments for renal or hepatic impairment are informed by recommendations from European Society of Endocrinology and hospital formularies at institutions like Guy's and St Thomas' NHS Foundation Trust and Johns Hopkins Hospital.

Interactions

Gliclazide interacts with agents that modify cytochrome P450 activity or alter glucose homeostasis, as documented in compendia from Micromedex, Liverpool Drug Interactions Group, and advisories by Food and Drug Administration panels. Co-administration considerations include drugs such as warfarin, beta-adrenergic blockers (e.g., propranolol), rifampicin, fluconazole, and other hypoglycemic agents including insulin and metformin; interaction risks have been examined in pharmacovigilance studies by European Medicines Agency and clinical trials at Mayo Clinic.

Chemistry and formulations

Chemically classified within the sulfonylurea family, gliclazide's structure and synthesis have been described in chemical literature from Royal Society of Chemistry journals and patent filings by pharmaceutical companies and research groups affiliated with University of Basel and ETH Zurich. Formulations include immediate-release tablets and modified- or extended-release preparations developed and approved in territories overseen by regulatory bodies like European Medicines Agency, Therapeutic Goods Administration (Australia), and national agencies. Generic manufacturing and formulation studies have been published by industry partners and academic centers including University of Milan and Seoul National University Hospital.

Category:Sulfonylureas